TCGA-44-2656-01A-02R-0946-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.550
- INFLAMMATORY_RESPONSE+0.440
- PROTEIN_SECRETION+0.440
- IL6_JAK_STAT3_SIGNALING+0.420
- COMPLEMENT+0.400
- KRAS_SIGNALING_UP+0.360
- TNFA_SIGNALING_VIA_NFKB+0.330
- ANDROGEN_RESPONSE+0.320
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.390
- E2F_TARGETS-0.310
- KRAS_SIGNALING_DN-0.310
- G2M_CHECKPOINT-0.300
- HEDGEHOG_SIGNALING-0.300
- MYC_TARGETS_V2-0.240
- MYC_TARGETS_V1-0.180
- SPERMATOGENESIS-0.160
- MITOTIC_SPINDLE-0.150
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195658 | — | — | 0.883 |
| 2 | SRR26320072 | — | — | 0.878 |
| 3 | DRR168598 | — | — | 0.867 |
| 4 | SRR12696766 | — | — | 0.864 |
| 5 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.864 |
| 6 | BS_S1KK7XRH | low-grade glioma | — | 0.854 |
| 7 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.853 |
| 8 | SRR934884 | — | — | 0.852 |
| 9 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.852 |
| 10 | SRR934924 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.320 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |